Treatment of insulin resistance

• US 5,281,581 A
• Filed: 06/19/1992
• Issued: 01/25/1994
• Est. Priority Date: 01/11/1988
• Status: Expired due to Fees

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Greene, Howard Jr., Cooper, Garth J. S.
• Primary Examiner(s): LEE, LESTER
• Application Number:
  US07/901,602
• Time in Patent Office: 585 Days
• Field of Search: 514/12, 514/13, 514/14, 514/15, 428/85.8
• US Class Current: 514/5.9
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors

Abstract

Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP], or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotype antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.

Claims

1. A method for treating insulin resistance in a subject comprising administering to said subject an amount of an amylin antagonist effective to reduce insulin resistance in said subject.

3. The method of claim 1 wherein said amylin antagonist is an amylin receptor antagonist.

2. A method for alleviating insulin suppression in pancreatic tissue of a subject comprising administering to said subject an amount of an amylin antagonist effective to reduce said insulin suppression in said subject.

4. The method of claim 2 wherein said amylin antagonist is an amylin receptor antagonist.